Subscribe

Featured Content

    Top Trending Articles

    FDA Approvals, News & Updates

    Highlights from the Latest Issue: December 2023, Vol 14, No 6

    Value-Based Care

    Personalized Medicine | Browse By Specialty

    Hematologic Malignancies

    Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
    Phoebe Starr
    Chicago, IL—Interim results from the phase 3 COMMANDS trial demonstrated that first-line treatment with luspatercept-aamt (Reblozyl) increased hemoglobin levels and enabled nearly twice as many patients with transfusion-dependent, lower-risk myelodysplastic syndromes (MDS) to avoid red blood cell transfusions during the first 24 weeks of the study compared with standard-of-care epoetin alfa.
    Read Article

    Quick Quiz: Chronic Myeloid Leukemia

    Quick Quiz: Chronic Myeloid Leukemia

    Chronic myeloid leukemia, also known as chronic myelogenous leukemia, is a malignancy that originates in blood-forming cells (called myeloid cells) found in bone marrow. How much do you know about chronic myeloid leukemia?

    Start the Quiz

    All previous issues of Value-Based Cancer Care are available here. Browse the digital archive below or use the search page to find a specific article you're looking for.

    Value-Based Cancer Care Issues By Year

    Latest Videos

    We Want to Know

    *Is access to care an obstacle for patients today?


    SPAM Check, leave blank

    Stay In The Know

    Stay up to date on the matters of value in cancer by signing up for the free, bi-monthly VBCC print publication and VBCC weekly e‑newsletter.

    Subscribe
    © Amplity Health. All Rights Reserved. Privacy Policy.